Literature DB >> 34189576

SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.

Patricia Balsas1,2, Luis Veloza3, Guillem Clot1,2, Marta Sureda-Gómez1, Marta-Leonor Rodríguez1, Christos Masaoutis3, Gerard Frigola3, Alba Navarro1,2, Silvia Beà1,2,3, Ferran Nadeu1,2, Eva Giné1,2,4, Armando López-Guillermo1,2,4, Antonio Martínez1,2,3, Inmaculada Ribera-Cortada3, Pablo Engel5, Leticia Quintanilla-Martínez6, Wolfram Klapper7, Elias Campo1,2,3, Virginia Amador1,2.   

Abstract

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a heterogeneous clinical and biological behavior. SOX11 oncogenic expression contributes to the aggressiveness of these tumors by different mechanisms, including tumor and stromal cell interactions. However, the precise composition of the immune cell microenvironment of MCL, its possible relationship to SOX11 expression, and how it may contribute to tumor behavior is not well known. Here, we performed an integrative transcriptome analysis of 730 immune-related genes combined with the immune cell phenotype analysis by immunohistochemistry in SOX11+ and SOX11- primary nodal MCL cases and non-neoplastic reactive lymph nodes. SOX11+ MCL had a significant lower T-cell intratumoral infiltration compared with negative cases. A reduced expression of MHCI/II-like and T-cell costimulation and signaling activation related transcripts was significantly associated with poor clinical outcome. Moreover, we identified CD70 as a SOX11 direct target gene, whose overexpression was induced in SOX11+, but not SOX11- tumor cells by CD40L in vitro. CD70 was overexpressed in primary SOX11+ MCL and it was associated with an immune unbalance of the tumor microenvironment characterized by increased number of effector regulatory t (Treg) cell infiltration, higher proliferation, and aggressive clinical course. CD27 was expressed with moderate to strong intensity in 76% of cases. Overall, our results suggest that SOX11 expression in MCL is associated with an immunosuppressive microenvironment characterized by CD70 overexpression in tumor cells, increased Treg cell infiltration and downmodulation of antigen processing, and presentation and T-cell activation that could promote MCL progression and represent a potential target for tailored therapies.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34189576      PMCID: PMC8641098          DOI: 10.1182/blood.2020010527

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma.

Authors:  Ying Zhu; Jaakko Hollmén; Riikka Räty; Yan Aalto; Balint Nagy; Erkki Elonen; Juha Kere; Heikki Mannila; Kaarle Franssila; Sakari Knuutila
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

2.  Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.

Authors:  René Scholtysik; Inga Nagel; Markus Kreuz; Inga Vater; Maciej Giefing; Carsten Schwaenen; Swen Wessendorf; Lorenz Trümper; Markus Loeffler; Reiner Siebert; Ralf Küppers
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

3.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.

Authors:  C Royo; A Navarro; G Clot; I Salaverria; E Giné; P Jares; D Colomer; A Wiestner; W H Wilson; M C Vegliante; V Fernandez; E M Hartmann; N Trim; W N Erber; S H Swerdlow; W Klapper; M J S Dyer; M Vargas-Pabón; G Ott; A Rosenwald; R Siebert; A López-Guillermo; E Campo; S Beà
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

4.  Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Zhi-Zhang Yang; Anne J Novak; Steven C Ziesmer; Thomas E Witzig; Stephen M Ansell
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

Review 5.  CD70: An emerging target in cancer immunotherapy.

Authors:  J Jacobs; V Deschoolmeester; K Zwaenepoel; C Rolfo; K Silence; S Rottey; F Lardon; E Smits; P Pauwels
Journal:  Pharmacol Ther       Date:  2015-07-26       Impact factor: 12.310

6.  Expression of the murine CD27 ligand CD70 in vitro and in vivo.

Authors:  Kiki Tesselaar; Yanling Xiao; Ramon Arens; Gijs M W van Schijndel; Danita H Schuurhuis; Reina E Mebius; Jannie Borst; René A W van Lier
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

7.  Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway.

Authors:  Jonathan M Coquet; Julie C Ribot; Nikolina Bąbała; Sabine Middendorp; Gerda van der Horst; Yanling Xiao; Joana F Neves; Diogo Fonseca-Pereira; Heinz Jacobs; Daniel J Pennington; Bruno Silva-Santos; Jannie Borst
Journal:  J Exp Med       Date:  2013-04-01       Impact factor: 14.307

8.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

9.  Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Authors:  Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

10.  Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.

Authors:  Martina Rudelius; Mathias Tillmann Rosenfeldt; Ellen Leich; Hilka Rauert-Wunderlich; Antonio Giovanni Solimando; Andreas Beilhack; German Ott; Andreas Rosenwald
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

View more
  3 in total

Review 1.  Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.

Authors:  Khalil Saleh; Morgane Cheminant; David Chiron; Barbara Burroni; Vincent Ribrag; Clémentine Sarkozy
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 2.  CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies.

Authors:  Katsiaryna Marhelava; Marta Krawczyk; Malgorzata Firczuk; Klaudyna Fidyt
Journal:  Cells       Date:  2022-05-31       Impact factor: 7.666

Review 3.  Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.

Authors:  Kamira Maharaj; Angimar Uriepero; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.